In its recent evaluation of alectinib, the French health authority stated that, in light of the superior efficacy and safety of alectinib compared to crizotinib demonstrated in the ALEX trial, alectinib should be the treatment of choice in the first line treatment of ALK+ lung cancer [36]. The gene discussed is ALK; the disease is lung carcinoma.